GlaucomaLYNXNCT01265719
Long-Term Non-Interventional Latanoprost Study
An observational study of Glaucoma and Ocular Hypertension, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 29 sites in 14 countries.
Trial summary
This is a non-interventional, prospective, longitudinal cohort study. A total of 150 pediatric subjects with glaucoma or elevated intraocular pressure, including 75 latanoprost-treated subjects and 75 non-topical prostaglandin analogue treated subjects, will be enrolled from ophthalmic hospital clinics and academic… Read more about this study
- Who is it for?
- Ages 1 day to 17 years
- Conditions the study is for
- Glaucoma, Ocular Hypertension
- How many people
- 175 participants
- Where
- 29 sitesin 14 countries
- Study dates
- Dec 2010to Feb 2016
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 day to 17 years
- All sexes
- No healthy volunteers
- Child
Study population: Pediatric populations diagnosed with glaucoma or elevated intraocular pressure
Who may be able to join
- Male or female <18 years of age (neonates must be at least 36 weeks gestational age).
- Diagnosis of pediatric glaucoma or elevated intraocular pressure.
- Evidence of a personally signed and dated informed consent document indicating that the subject (and/or a legally acceptable representative) has been informed of all pertinent aspects of the study. A signed and dated assent will be required where applicable according to local laws.
- For treated subjects only:
- Continuously treated with latanoprost for at least 1 month within the year prior to the baseline examination.
- For untreated subjects only:
- Continuously treated with latanoprost or other topical prostaglandin analogues for less than one month prior to the baseline examination (based on the best knowledge of treating ophthalmologists), and unlikely to be treated with latanoprost or other topical prostaglandin analogues during the three-year study period; OR
- No prior treatment with latanoprost or other topical prostaglandin analogues, and unlikely to be treated with latanoprost or other topical prostaglandin analogues during the three-year study period.
Who cannot join
- Unable/unwilling to comply with protocol.
- Pregnant or nursing females at baseline.
- For treated subjects only: a history of allergy or hypersensitivity to any of the ingredients contained in latanoprost (e.g., hypersensitivity to benzalkonium chloride).
Trial locations and contacts
29 sites in 14 countries.
29 sites in 14 countries
Italy4 sites
Azienda Ospedaliero Univ.
Catania, CT, 95123
Ospedale Pediatrico Bambino Gesu
Fiumicino (Roma), 00050
Istituto Giannina Gaslini, Divisione di Oculistica
Genova, 16147
Unita' Operativa di Oculistica Pediatrica, Azienda Ospedaliera Ospedale Niguarda Ca'Grande
Milan, 20162
Spain4 sites
Hospital Sant Joan de Deu
Esplugues de Llobregat, Barcelona, 08950
Hospital Clinico San Carlos
Madrid, 28040
Hospital Virgen Del Rocio
Seville, 41013
Hospital Universitario Miguel Servet
Zaragoza, 50009
France3 sites
CHU d'Amiens -Centre Saint Victor
Amiens, 80000
Hopital Claude Huriez
Lille, 59037
Fondation Ophtalmologique Adolphe de Rothschild
Paris, Cedex 19, 75940
Germany3 sites
Universitaetsklinikum Giessen und Marburg
Giessen, 35392
Universitaetsklinikum Hamburg-Eppendorf
Hamburg, 20246
Universitaetsklinikum Mainz
Mainz, 55131
United Kingdom3 sites
Birmingham and Midland Eye Centre, Consultant Ophthalmologist
Birmingham, B18 7QH
Richard Desmond Childrens Eye Centre
London, EC1V 2PD
Manchester Royal Eye Hospital
Manchester, GT MAN, M13 9WH
Belgium2 sites
Universitair Ziekenhuis Antwerpen, Dienst Oftalmologie
Edegem, 2650
Universitair Ziekenhuis Leuven - Campus Sint-Raphaël
Leuven, 3000
Czechia2 sites
Fakultni nemocnice Brno
Brno, 613 00
Fakultni nemocnice v Motole
Prague, 150 06
Sweden2 sites
Akademiska Sjukhuset
Uppsala, 751 85
Ögonkliniken, Centrallasarettet
Västerås, 721 89
Greece1 site
University General Hospital of Thessaloniki AHEPA
Thessaloniki, 54636
Portugal1 site
AIBILI - Associação para a Investigação Biomédica e Inovação em Luz e Imagem
Coimbra, 3000-548
Slovakia1 site
Detska Fakultna nemocnica s poliklinikou Bratislava
Bratislava, 83340
About this study
Official title: A Prospective, Non-interventional, Longitudinal Cohort Study To Evaluate The Long-term Safety Of Latanoprost Treatment In Pediatric Populations
This is a non-interventional, prospective, longitudinal cohort study. A total of 150 pediatric subjects with glaucoma or elevated intraocular pressure, including 75 latanoprost-treated subjects and 75 non-topical prostaglandin analogue treated subjects, will be enrolled from ophthalmic hospital clinics and academic ophthalmic centers. As a non-interventional study, the study subjects' continued use of latanoprost and assessments of ocular events will be obtained through the routine medical follow-up with treating ophthalmologists or other designated members of the medical care team.
Read the detailed description
At least 40 subjects in each of the following age groups: 1-<5 years and 5-<18 years. No minimum required numbers in the <1 year age group.
- Conditions
- Glaucoma, Ocular Hypertension
- Being tested
- No intervention other than routine medical care
- Keywords
- Prospective, non-interventional, longitudinal, cohort study
- Medical subject headings
- Glaucoma, Ocular Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No intervention other than routine medical careOther
Also called Observational
Subjects continuously treated with Latanoprost for at least one month Latanoprost treatment during the study period.
No intervention other than routine medical careOther
Also called Observational
Subjects not treated with any topical prostaglandin analogues or continuously treated with topical prostaglandin analogues for less than one month before the baseline examination, and unlikely to be treated with topical prostaglandin analogues during the study period.
| Study group | Role | What they receive |
|---|---|---|
| Latanoprost-treatment group | Not described Receives: Other: No intervention other than routine medical care | |
| Non-topical prostaglandin analogue treatment group | Not described Receives: Other: No intervention other than routine medical care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline to Last Available Observation in Best Corrected Visual Acuity (BCVA) (Snellen or Equivalent)
Patients familiar with the letters of the alphabet were evaluated using Snellen visual acuity. Patients who were unable or unfamiliar with the letters of the alphabet were evaluated using charts made up of numbers, pictures (eg, Schering's Children's Eye Chart or Allen Cards), E's, or Landolt's broken rings, and other methods which were equivalent to Snellen acuity eg, HOTV testing).
Measured: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months
Secondary outcomes (13)
Number of Participants With Clinically Meaningful Change in Refractive Error
The refractive error [cycloplegic where appropriate (eg, those unable to cooperate with manifest refraction)] were determined at the baseline visit and assessed at the following visits.
Measured: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months
Change From Baseline to Last Available Observation in Horizontal Corneal Diameter (by Caliper and/or Ruler)
The horizontal corneal diameter was measured along the horizontal meridians. Diameter was measured using either a series of transparent plates with holes of different diameters in quarter-millimeter increments or with calibrated calipers compared against a ruler. When using calipers, the corneal diameter measurement was taken from limbus to a similar point 180° away at the opposite limbus. When not examining the children with anesthesia, it was recommended to use a tape measure across the head while measuring horizontal corneal diameter by photographic method.
Measured: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months
Change From Baseline to Last Available Observation in Intraocular Pressure (IOP)
IOP was preferably measured using 1 of 3 applanation-contact methods: Goldmann applanation tonometry, Perkins tonometry, or TonoPen® (tonometry). iCare® rebound tonometer was also allowed if it was used consistently throughout the study.
Measured: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months
Cup-to-disc Ratio (for Assessment of Optic Nerve Changes/Structures) - Number of Participants With Clinically Significant Deterioration in Cup/Disc Ratios
The cup/disc ratio was recorded horizontally and vertically for each examination, and reported in 0.1 increments.
Measured: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months
Visual Field Defects - Number of Participants With Clinically Significant Deterioration of Visual Field Defects.
A visual field examination was performed for those patients who can cooperate automated perimetry utilizing a threshold program. All visual fields was conducted utilizing the standard white background with a Goldmann size III white stimulus. For those patients who can not perform formal visual field testing, then field to confrontation test was used for younger, non-verbal children, central, steady and maintains fixation was used.
Measured: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months
Iris Color Darkening
Changes from baseline in iris color were reported at each follow-up visit. Photographs were taken at the discretion of investigators as per standard of care.
Measured: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months
Localized Pigmentation (Nevi or Freckles) of Conjunctiva, Iris and Choroid
Changes from baseline in localized pigmentation (nevi and freckles) of the conjunctiva, iris and choroid were reported at each follow-up visit. Photographs were taken at the discretion of investigators as per standard of care.
Measured: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months
Eyelash Darkening/Thickening
Changes from baseline in eyelash darkening/thickening/lengthening were reported at each follow-up visit. Photographs were taken at the discretion of investigators as per standard of care.
Measured: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months
Change From Baseline to Last Available Observation in Length of Eyelash (by Caliper and/or Ruler)
The longest eyelash (mm) measured by caliper or ruler was recorded at baseline and each follow-up visit.
Measured: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months
Change From Baseline to Last Available Observation in Corneal Thickness (Pachymeter)
Central corneal thickness was measured using a calibrated pachymeter, preferably an ultrasonic pachymeter.
Measured: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months
Conjunctival/Ocular Hyperemia
Conjunctiva hyperemia was assessed by slit-lamp examination. When slit-lamp examination is not possible due to subject cooperation, a fixation light and 20-diopter lens (for magnification) was used to assess this parameter. Conjunctival hyperemia was assessed and graded by ophthalmologist at baseline and follow-up visits from grades 0-3 and is as follows:
0 = None, Normal: few vessels of palpebral or bulbar conjunctiva easily observed
- = Mild, Reddening of the palpebral or bulbar conjunctiva
- = Moderate, Bright reddening of the palpebral or bulbar conjunctiva
- = Severe, Deep, bright, and diffuse reddening of the palpebral or bulbar conjunctiva
Measured: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months
Number of Participants With a Change in Anterior Segment Biomicroscopy
Slit-lamp biomicroscopy (mounted or hand-held) without fluorescein and without dilation of the pupil was performed. When slit-lamp examination was not possible, a fixation light and 20-diopter lens (for magnification) was used. At each scheduled visit, deposition of pigment on the corneal endothelial layer or the lens capsule or any abnormalities of the lids, conjunctivae, cornea, anterior chamber, iris, or lens was examined.
Measured: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months
Number of Participants With Abnormalities in Fundoscopy Posterior Segment at Baseline
Fundoscopy was performed after dilation of the pupils (eg, 1 % tropicamide or cyclopentolate and 2 ½ % phenylephrine, or a clinically- appropriate dose according to the clinician's standard care of each particular patient). The examination included an evaluation of the vitreous body, retina (including the macula), and optic nerve head.
The fundoscopy e-CRF was completed only at baseline because the investigators were required to perform slit lamp, direct or indirect ophthalmoscopy at each visit and report any AEs observed which included the vitreous, retina and optic nerve.
Measured: Evaluated at Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Dec 2010 (estimated)
- Study startDec 2010
- Primary completionFeb 2016
- Study completionFeb 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for GlaucomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 175 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01265719
- Sponsor's protocol ID
- A6111143
- Other IDs
- PFI-LAT-2009-01, LYNX
- Acronym
- LYNX
- Status last verified
- Feb 2018
- First submitted
- 16 Dec 2010
- Last updated
- 3 Feb 2021
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Feb 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Non-interventional, Longitudinal Cohort Study To Evaluate The Long-term Safety Of Latanoprost Treatment In Pediatric Populations
- ClinicalTrials.gov ID
- NCT01265719
- Acronym / sponsor ID
- LYNX / A6111143
- Conditions
- Glaucoma, Ocular Hypertension
- Keywords
- Prospective, non-interventional, longitudinal, cohort study
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 175 participants (actual)
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Industry (pharma, biotech, devices)
- Study start
- Dec 2010 (actual)
- Primary completion
- Feb 2016 (actual)
- Study completion
- Feb 2016 (actual)
- First posted
- 23 Dec 2010 (estimated)
- Results
- Posted 5 Nov 2018
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a non-interventional, prospective, longitudinal cohort study. A total of 150 pediatric subjects with glaucoma or elevated intraocular pressure, including 75 latanoprost-treated subjects and 75 non-topical prostaglandin analogue treated subjects, will be enrolled from ophthalmic hospital clinics and academic ophthalmic centers. As a non-interventional study, the study subjects' continued use of latanoprost and assessments of ocular events will be obtained through the routine medical follow-up with treating ophthalmologists or other designated members of the medical care team.
Detailed description
At least 40 subjects in each of the following age groups: 1-<5 years and 5-<18 years. No minimum required numbers in the <1 year age group.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Latanoprost-treatment group | – | Other: No intervention other than routine medical care |
| Non-topical prostaglandin analogue treatment group | – | Other: No intervention other than routine medical care |
Who may qualify
- Ages
- 1 day to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
- Study population
- Pediatric populations diagnosed with glaucoma or elevated intraocular pressure
Key inclusion criteria (8 listed)
- Male or female <18 years of age (neonates must be at least 36 weeks gestational age).
- Diagnosis of pediatric glaucoma or elevated intraocular pressure.
- Evidence of a personally signed and dated informed consent document indicating that the subject (and/or a legally acceptable representative) has been informed of all pertinent aspects of the study. A signed and dated assent will be required where applicable according to local laws.
- Continuously treated with latanoprost for at least 1 month within the year prior to the baseline examination.
- Continuously treated with latanoprost or other topical prostaglandin analogues for less than one month prior to the baseline examination (based on the best knowledge of treating ophthalmologists), and unlikely to be treated with latanoprost or other topical prostaglandin analogues during the three-year study period; OR
Key exclusion criteria (3 listed)
- Unable/unwilling to comply with protocol.
- Pregnant or nursing females at baseline.
- For treated subjects only: a history of allergy or hypersensitivity to any of the ingredients contained in latanoprost (e.g., hypersensitivity to benzalkonium chloride).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No intervention other than routine medical careAlso: ObservationalSubjects continuously treated with Latanoprost for at least one month Latanoprost treatment during the study period. | Other | Latanoprost-treatment group |
| No intervention other than routine medical careAlso: ObservationalSubjects not treated with any topical prostaglandin analogues or continuously treated with topical prostaglandin analogues for less than one month before the baseline examination, and unlikely to be treated with topical prostaglandin analogues during the study period. | Other | Non-topical prostaglandin analogue treatment group |
Primary outcome
Change From Baseline to Last Available Observation in Best Corrected Visual Acuity (BCVA) (Snellen or Equivalent)
Time frame: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months
Patients familiar with the letters of the alphabet were evaluated using Snellen visual acuity. Patients who were unable or unfamiliar with the letters of the alphabet were evaluated using charts made up of numbers, pictures (eg, Schering's Children's Eye Chart or Allen Cards), E's, or Landolt's broken rings, and other methods which were equivalent to Snellen acuity eg, HOTV testing).
13 secondary outcomes
Number of Participants With Clinically Meaningful Change in Refractive Error
Time frame: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months
Change From Baseline to Last Available Observation in Horizontal Corneal Diameter (by Caliper and/or Ruler)
Time frame: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months
Change From Baseline to Last Available Observation in Intraocular Pressure (IOP)
Time frame: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months
Cup-to-disc Ratio (for Assessment of Optic Nerve Changes/Structures) - Number of Participants With Clinically Significant Deterioration in Cup/Disc Ratios
Time frame: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months
Visual Field Defects - Number of Participants With Clinically Significant Deterioration of Visual Field Defects.
Time frame: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months
Iris Color Darkening
Time frame: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months
Localized Pigmentation (Nevi or Freckles) of Conjunctiva, Iris and Choroid
Time frame: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months
Eyelash Darkening/Thickening
Time frame: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months
Change From Baseline to Last Available Observation in Length of Eyelash (by Caliper and/or Ruler)
Time frame: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months
Change From Baseline to Last Available Observation in Corneal Thickness (Pachymeter)
Time frame: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months
Conjunctival/Ocular Hyperemia
Time frame: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months
Number of Participants With a Change in Anterior Segment Biomicroscopy
Time frame: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months
Number of Participants With Abnormalities in Fundoscopy Posterior Segment at Baseline
Time frame: Evaluated at Baseline
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Feb 2021.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
Related trials for Glaucoma
RecruitingObservational study
PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group
Primary Open Angle Glaucoma
RecruitingPhase 4
Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma Patients
Open Angle Glaucoma (OAG), Glaucoma
Active, not recruitingObservational study
Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults
Primary Open Angle Glaucoma
Active, not recruitingObservational study
Impact of Glaucoma and Visual Field Loss on Life Space
Primary Open-angle Glaucoma
Recruiting
Inflammatory Mediators of Glaucoma After Corneal Transplantation (AH-Tears)
Glaucoma, Corneal Transplantation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
29 sites in 14 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Glaucoma and Ocular Hypertension, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 29 sites in 14 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 29 sites in Italy, Spain, France, Germany, United Kingdom and 9 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 5 Nov 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline to Last Available Observation in Best Corrected Visual Acuity (BCVA) (Snellen or Equivalent) (time frame: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Feb 2021.